- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03752619
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kristine Hansen, PT
- Phone Number: 216-957-3584
- Email: khansen1@metrohealth.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44109
- MetroHealth Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- Univerity of Texas Southwestern
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Shoulder pain of >3 months
- Age>=21
- Worst pain in the last week>=4 (0-10 scale)
- Ability to check skin and perform dressing changes, independently or with assistance
- Stable dose of pain medication (Not taking more than than 1 opioid or 1 non-opioid analgesic)
Exclusion Criteria:
- Current shoulder joint or overlying skin infection, or current bacterial infection requiring antibiotics
- Other chronic pain syndrome (Pain in another area of the body 15 or more days in the last 30 (more than half of the time) or taking daily analgesics for another pain syndrome)
- Prior shoulder surgery to ipsilateral shoulder joint (glenohumeral, rotator cuff, acromioclavicular (AC) Joint, etc.)
- Corticosteroid injection in the ipsilateral shoulder or any other pain relieving treatment in last 12 weeks
- Uncontrolled bleeding disorder
- Medical instability based on physician opinion after review of medical information
- Pregnancy
- Neurological condition affecting ipsilateral upper limb (such as central neurologic injury/illness, radiculopathy, diabetic amyotrophy, Complex Regional Pain Syndrome, etc.)
- Current Worker's compensation claim for the ipsilateral shoulder
- Shoulder instability, severe glenohumeral osteoarthritis(OA) based on patient symptoms and physical examination
- Ipsilateral shoulder injury due to severe trauma (Fall from greater than standing height; Motor vehicle crashes; Struck by vehicle or other fast-moving projectile (e.g., bullet, baseball, etc.); Assault (i.e., injuries intentionally inflicted by another person))
- Current osseus fracture in ipsilateral arm
- Ipsilateral upper limb amputation other than a single digit (digits 2-5, partial or full)
- Surgical indication for shoulder treatment based on physician opinion
- Compromised immune system (immunodeficiency or immunosuppression)
- Current use of a Deep Brain Stimulation (DBS) system, implanted active cardiac implant (e.g. pacemaker or defibrillator), any other implantable neuro-stimulator whose stimulus current pathway may overlap with that of the SPRINT System
- Patients who have a tape or adhesive allergy
- Contraindication to Magnetic resonance imaging (metal in body, claustrophobia, body habitus, etc) - exclude from Magnetic resonance imaging (MRI) only
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Contraction Producing Peripheral Nerve Stimulation
This group will receive: 1) muscle contraction producing peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily); and, 2) physical therapy.
|
The stimulation system includes an external stimulator, percutaneous lead and pad.
The stimulator snaps onto the pad.
The pad has an embedded power source but also serves as the anode.
The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS).
The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip.
After a 1-week stabilization period, stimulation is initiated (6 hrs/day).
The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate.
The treatment period is 3 weeks after which the lead will be removed.
Other Names:
All participants receive eight 1.0 hr.
sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment.
Each participant also performs home exercises.
The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb.
During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
|
Active Comparator: Non Contracting Producing Peripheral Nerve Stimulation
This group will receive: 1) non contraction producing peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily); and, 2) physical therapy.
|
All participants receive eight 1.0 hr.
sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment.
Each participant also performs home exercises.
The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb.
During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
The stimulation system includes an external stimulator, percutaneous lead and pad.
The stimulator snaps onto the pad.
The pad has an embedded power source but also serves as the anode.
The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS).
The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip.
After a 1-week stabilization period, stimulation is initiated (6 hrs/day).
The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate.
The treatment period is 3 weeks after which the lead will be removed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in - Short Form (SF) question 3 (BPI-SF3)
Time Frame: Prior 7-days] ; Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
The Brief Pain Inventory (BPI)has excellent psychometrics.
The developers of the Brief Pain Inventory (BPI) recommend Brief Pain Inventory (BPI )3, the "pain worst" rating, as the primary response metric.
The question asks participants to rate their worst pain in the prior 24-hours OR prior 7-day on a 0 to 10 Numerical Rating Scale (NRS), where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine."
|
Prior 7-days] ; Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Brief Pain Inventory (BPI)- Short Form (SF)
Time Frame: Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning.
The question asks participants to rate their pain in the prior 24-hours OR prior 7-day on a 0 to 10 Numerical Rating Scale (NRS), where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine."
."
In addition, the question asks the participant to rate how their pain interferes with daily activities where "0" indicates "does not interfere and "10" indicates "completely interferes".
|
Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
Change in Activities of Daily Living(ADL( capacity - Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA)
Time Frame: Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
The Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA) is a laboratory based objective measure of ADL capacity.
The Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA) is a timed test that provides a brief measure of functional ability of the upper limb while performing multi-level tasks that require grip/manipulation of the hand, elbow/shoulder reaching, sustained overhead work, and sustained positioning with an emphasis on assessing the limitations in functional capacity attributable to shoulder and neck disorders
|
Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
Change in Activities of Daily Living (ADL) performance -Shoulder Pain and Disability Index (SPADI)
Time Frame: Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
The Shoulder Pain and Disability Index (SPADI) is a self-administered questionnaire that consists of two dimensions, one for pain and the other for functional activities.
The pain dimension consists of five questions regarding the severity of an individual's pain.
Functional activities are assessed with eight questions designed to measure the degree of difficulty an individual has with various activities of daily living that require upper-extremity use.The question asks severity of pain based on an 0-10 numerical Rating Scale where 0 = no pain and 10 = the worst pain imaginable.
In addition, it asks how much difficulty the participant has on a numerical rating scale where 0 = no difficulty and 10 = so difficult it requires help.
Total disability score: _____/ 80 x 100 = % Total SPADI score: _____ 130 x 100 = % Minimum Detectable Change (90% confidence) = 13 points (Change less than this may be attributable to measurement error).
lower score is better.
|
Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
Change in Quality of life - Short form - 12(QoL - SF 12)
Time Frame: Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
Quality of life - Short form - 12 (QoL - SF 12) is a health related Quality of life (QoL) measure that assesses physical functioning, role limitation because of physical health problems, bodily pain, social functioning, general mental health, role. Scoring: Two summary scores are a mental component score (MCS-12) and a physical component score (PCS-12). The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). The United States population average PCS-12 and MCS-12 are both 50 points. Lower score is better. |
Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
Change Mechanical Quantitative Sensory Testing (QST)
Time Frame: Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
used to evaluate central sensitization
|
Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Adverse events
Time Frame: Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
Related adverse events are documented as Safety data.
|
Baseline (week 1), End of Treatment(week 5), 12 weeks post treatment, 24 weeks post treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard D Wilson, MD, MetroHealth Medical Center
Publications and helpful links
General Publications
- Arroll B, Goodyear-Smith F. Corticosteroid injections for painful shoulder: a meta-analysis. Br J Gen Pract. 2005 Mar;55(512):224-8.
- Johansson K, Oberg B, Adolfsson L, Foldevi M. A combination of systematic review and clinicians' beliefs in interventions for subacromial pain. Br J Gen Pract. 2002 Feb;52(475):145-52.
- van der Windt DA, Koes BW, de Jong BA, Bouter LM. Shoulder disorders in general practice: incidence, patient characteristics, and management. Ann Rheum Dis. 1995 Dec;54(12):959-64. doi: 10.1136/ard.54.12.959.
- Urwin M, Symmons D, Allison T, Brammah T, Busby H, Roxby M, Simmons A, Williams G. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. Ann Rheum Dis. 1998 Nov;57(11):649-55. doi: 10.1136/ard.57.11.649.
- Johnson MP, Crossley KL, O'neil ME, Al-Zakwani IS. Estimates of Direct Health Care Expenditures Among Individuals With Shoulder Dysfunction in the United States J Ortho Sports Phys Ther 2005;35(1,A4).
- Cadogan A, Laslett M, Hing WA, McNair PJ, Coates MH. A prospective study of shoulder pain in primary care: prevalence of imaged pathology and response to guided diagnostic blocks. BMC Musculoskelet Disord. 2011 May 28;12:119. doi: 10.1186/1471-2474-12-119.
- Crawshaw DP, Helliwell PS, Hensor EM, Hay EM, Aldous SJ, Conaghan PG. Exercise therapy after corticosteroid injection for moderate to severe shoulder pain: large pragmatic randomised trial. BMJ. 2010 Jun 28;340:c3037. doi: 10.1136/bmj.c3037.
- Cummins CA, Sasso LM, Nicholson D. Impingement syndrome: temporal outcomes of nonoperative treatment. J Shoulder Elbow Surg. 2009 Mar-Apr;18(2):172-7. doi: 10.1016/j.jse.2008.09.005. Epub 2008 Dec 18.
- Litaker D, Pioro M, El Bilbeisi H, Brems J. Returning to the bedside: using the history and physical examination to identify rotator cuff tears. J Am Geriatr Soc. 2000 Dec;48(12):1633-7. doi: 10.1111/j.1532-5415.2000.tb03875.x.
- Morrison DS, Frogameni AD, Woodworth P. Non-operative treatment of subacromial impingement syndrome. J Bone Joint Surg Am. 1997 May;79(5):732-7. doi: 10.2106/00004623-199705000-00013.
- Cleland T, Jain NB, Chae J, Hansen KM, Hisel TZ, Gunzler DD, Whitehair VC, Kim CH, Wilson RD. The protocol for a multisite, double blind, randomized, placebo-controlled trial of axillary nerve stimulation for chronic shoulder pain. Trials. 2020 Mar 6;21(1):248. doi: 10.1186/s13063-020-4174-x.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB17-00643
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shoulder Impingement Syndrome
-
Mahidol UniversityCompletedSubacromial Impingement Syndrome | Shoulder Impingement Syndrome | Subacromial Pain Syndrome | Subacromial Impingement | Impingement Syndrome, ShoulderIndonesia
-
Copenhagen University Hospital, HvidovreUniversity of Copenhagen; Aalborg University; Metropolitan University CollegeCompletedSubacromial Impingement SyndromeDenmark
-
Uskudar State HospitalNot yet recruitingSubacromial Impingement Syndrome | Shoulder Impingement Syndrome | Shoulder Pain | Subacromial Impingement | Shoulder Impingement
-
King Saud UniversityUnknownImpingement Syndrome, ShoulderSaudi Arabia
-
Hadassah Medical OrganizationUnknownShoulder Impingement Syndrome.
-
National Taiwan University HospitalCompletedShoulder Impingement Syndrome (SIS); Round Shoulder Posture (RSP)Taiwan
-
Central Finland Hospital DistrictOulu University Hospital; Academy of FinlandActive, not recruitingSubacromial Impingement SyndromeFinland
-
Linkoeping UniversityCompletedSubacromial Impingement SyndromeSweden
-
Cairo UniversityCompletedImpingement Syndrome, ShoulderEgypt
-
Sevgi Medical CenterCompletedSubacromial Impingement Syndrome | Subacromial ImpingementTurkey
Clinical Trials on Contracting Producing Peripheral Nerve Stimulation
-
MetroHealth Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Hospital Israelita Albert EinsteinFundação de Amparo à Pesquisa do Estado de São PauloRecruiting
-
University of California, San DiegoCopenhagen University Hospital at Herlev; University California Academic Senate and other collaboratorsCompletedPostoperative PainUnited States
-
Epineuron Technologies Inc.RecruitingNerve InjuryCanada, United States
-
MetroHealth Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruiting
-
Cantonal Hospital of St. GallenCompletedFecal IncontinenceSwitzerland
-
PD Dr. med. Simon BayerlRecruitingSacroiliac Joint PainGermany
-
MetroHealth Medical CenterRecruitingStroke | Gait, Hemiplegic | Gait, Spastic | Chronic Stroke | Walking, DifficultyUnited States
-
University of KentuckyCompletedStroke | Cerebrovascular Accident
-
University of Sao Paulo General HospitalNational Institute of Neurological Disorders and Stroke (NINDS); The Cleveland... and other collaboratorsCompleted